New hope for tough breast cancers: drug combo targets tumors before surgery
NCT ID NCT05675579
First seen Nov 05, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests whether giving two drugs (sacituzumab govitecan and pembrolizumab) before surgery can help control early-stage triple-negative breast cancer that hasn't responded well to standard chemotherapy and immunotherapy. About 27 adults with this type of breast cancer will receive the combination and be monitored for side effects and tumor response. The goal is to find a better treatment option for patients whose cancer is resistant to initial therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.